Literature DB >> 9536268

Transient immunosuppression with 15-deoxyspergualin prolongs reporter gene expression and reduces humoral immune response after adenoviral gene transfer.

G Cichon1, M Strauss.   

Abstract

A strong immune response against transgenic cells is one important limitation for long-term expression after adenoviral gene transfer in mammals. Continuous pharmacological immunosuppression has been shown to ameliorate immune reactions and to prolong reporter gene expression. In this study, we explored the effect of short-term immunosuppression for long-term gene expression and its impact on antibody formation. Immunosuppression with FK 506 (1 mg/kg/day), cyclosporin A (20 mg/kg/day) and 15-deoxyspergualin (10 mg/kg/day) was performed in NMRI mice. Expression of the reporter gene human alpha-1-antitrypsin (hAAT) and antibody formation was monitored for 7 months. A 5-day course of 15-deoxyspergualin (15-DSG) markedly slowed the decline of reporter gene expression and a positive effect was still detectable 200 days after gene transfer. At the same time, antibody production was reduced by 50-60%. Continuous treatment with 15-DSG (10 mg/kg twice weekly) led to a further small increase of gene expression but reduced antibody formation by 80-90%. A short course of FK 506 and cyclosporin A (CsA), had conferred a negative effect on gene expression. Both groups showed an even faster reduction in gene expression compared with the control group. The results of this investigation suggest that 15-DSG could serve as an effective supplement for viral gene therapy protocols.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9536268     DOI: 10.1038/sj.gt.3300555

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  7 in total

1.  Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo.

Authors:  C Hofmann; P Löser; G Cichon; W Arnold; G W Both; M Strauss
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Cell targeting in anti-cancer gene therapy.

Authors:  Mohd Azmi Mohd Lila; John Shia Kwong Siew; Hayati Zakaria; Suria Mohd Saad; Lim Shen Ni; Jafri Malin Abdullah
Journal:  Malays J Med Sci       Date:  2004-01

3.  Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs.

Authors:  B G Harvey; N R Hackett; T El-Sawy; T K Rosengart; E A Hirschowitz; M D Lieberman; M L Lesser; R G Crystal
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

4.  Pseudopackaging of adenovirus type 5 genomes into capsids containing the hexon proteins of adenovirus serotypes B, D, or E.

Authors:  P Ostapchuk; P Hearing
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

5.  High-efficiency system for the construction of adenovirus vectors and its application to the generation of representative adenovirus-based cDNA expression libraries.

Authors:  Moritz Hillgenberg; Christian Hofmann; Herbert Stadler; Peter Löser
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  Biology of ovine adenovirus infection of nonpermissive cells.

Authors:  Daniel Kümin; Christian Hofmann; Michael Rudolph; Gerald W Both; Peter Löser
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

7.  Construction, rescue, and characterization of vectors derived from ovine atadenovirus.

Authors:  Peter Löser; Christian Hofmann; Gerald W Both; Wolfgang Uckert; Moritz Hillgenberg
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.